Patent · US Active

Use of melanocortins to treat insulin sensitivity

US9827286B2 · kind B2 · utility

0Cited by

2References

10Claims

0Family size

Assignees

IPSEN PHARMA S.A.S. · FR
BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE · US

Inventors

Heather A. Halem · Westborough, US
Michael DeWitt Culler · Gretna, US
Andrew Butler · Kirkwood, US

Key dates

Filing date	Aug 22, 2016
Grant date	Nov 28, 2017
Priority date	—
Expiry date	Aug 22, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K7/64
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.